Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized placebo-controlled study of single and multiple ascending doses of GBR 830 in healthy adults
NL-OMON44196Phase 1Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of telazorlimab in autoimmune disease (4 arms), sponsored by Glenmark Pharmaceuticals SA. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Dose-limiting toxicities. Started Jul 2017; status: active, not recruiting.
02
Drugs
telazorlimab
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON44196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44196.